RAPIVAB  (peramivir injection)



Rapivab is to be given by infusion under medical supervision in a hospital setting or similar. Please contact your doctor or Healthcare Professional if you have any questions about this medicine or its use. Biocelect does not provide medical advice to patients or consumers. You will find information about your medicine in the Consumer Medicine Information below.

Rapivab is indicated for the treatment of acute influenza infection in adults and children 2 years and
older who have been symptomatic for no more than two days*.​

Copies of the Product Information and Consumer Medicine Information are available in the links below.

* Current TGA approved indication in Australia. RAPIVAB is currently TGA approved in Australia. RAPIVAB is not approved by MedSafe in New Zealand.

New Zealand

Biocelect Logo_Colour.png

Copyright 2019 Biocelect 

Australian Office: Suite 502, 139 Macquarie Street, Sydney NSW 2000, Australia

Registered Office Australia: Suite 405, Level 4, 51 Rawson Street, Epping NSW, 2121,  Australia 

Registered Office New Zealand: Level 5, Wynn Williams House, 47 Hereford Street, Christchurch 8013, New Zealand

Biocelect acknowledges the Traditional Custodians of Australia and their continued connection to land,

sea and community. We pay our respects to the Elders, past and present. 

Privacy Policy

  • LinkedIn Social Icon